

Carbenoxolone Blocks Endotoxin-Induced Protein Kinase R (PKR) Activation and High Mobility Group Box 1 (HMGB1) Release

Wei Li,^{1,2} Jianhua Li,¹ Andrew E Sama,² and Haichao Wang^{1,2}

¹The Feinstein Institute for Medical Research, Manhasset, New York, United States of America; ²Department of Emergency Medicine, North Shore University Hospital, Manhasset, New York, United States of America

The pathogen- and damage-associated molecular patterns (for example, bacterial endotoxin and adenosine 5'-triphosphate (ATP)) activate the double-stranded RNA-activated protein kinase R (PKR) to trigger the inflammasome-dependent high mobility group box 1 (HMGB1) release. Extracellular ATP contributes to the inflammasome activation through binding to the plasma membrane purinergic P2X₇ receptor (P2X₇R), triggering the opening of P2X₇R channels and the pannexin-1 (panx-1) hemichannels permeable for larger molecules up to 900 daltons. It was previously unknown whether panx-1 channel blockers can abrogate lipopolysaccharide (LPS)-induced PKR activation and HMGB1 release in innate immune cells. Here we demonstrated that a major gancan (licorice) component (glycyrrhizin, or glycyrrhizic acid) derivative, carbenoxolone (CBX), dose dependently abrogated LPS-induced HMGB1 release in macrophage cultures with an estimated IC₅₀ ≈ 5 μmol/L. In an animal model of polymicrobial sepsis (induced by cecal ligation and puncture (CLP)), repetitive CBX administration beginning 24 h after CLP led to a significant reduction of circulating and peritoneal HMGB1 levels, and promoted a significant increase in animal survival rates. As did P2X₇R antagonists (for example, oxidized ATP, oATP), CBX also effectively attenuated LPS-induced P2X₇R/panx-1 channel activation (as judged by Lucifer Yellow dye uptake) and PKR phosphorylation in primary peritoneal macrophages. Collectively, these results suggested that CBX blocks LPS-induced HMGB1 release possibly through impairing PKR activation, supporting the involvement of PKR in the regulation of HMGB1 release.

Online address: <http://www.molmed.org>

doi: 10.2119/molmed.2013.00064

INTRODUCTION

Sepsis is an overwhelming systemic inflammatory response to severe infections, and remains the primary cause of mortality in medical intensive care units. It afflicts approximately 750,000 Americans each year, and costs the United States healthcare system nearly \$17 billion annually (1). Current treatments are predominantly supportive and often ineffective, necessitating the continued search for effective therapies. The pathogenesis of sepsis is partly mediated by pathogen- and damage-associated molecular patterns

(for example, endotoxins, adenosine 5'-triphosphate [ATP] or high mobility group box 1 [HMGB1]) (2), which activate innate immune cells via binding to various pattern-recognition receptors (for example, toll-like receptor 4 [TLR4], P2X₇R, CD24, or Siglec-10) (3–5). For instance, crude endotoxins (containing trace amounts of bacterial proteins and nucleic acids) can stimulate macrophages to sequentially release early (for example, tumor necrosis factor [TNF], interleukin [IL]-1β and interferon [IFN]-γ) and late (for example, HMGB1) proinflammatory

mediators (6,7). In animal models of endotoxemia or sepsis, circulating HMGB1 levels plateau between 24 and 36 hours (6,8), distinguishing HMGB1 from other early cytokines (9). Moreover, HMGB1-neutralizing antibodies confer protection against lethal endotoxemia (6) and sepsis (8,10) even when given 24 hours after the onset of sepsis, establishing HMGB1 as a late mediator of lethal inflammatory diseases (11).

The mechanisms underlying the regulation of endotoxin-induced HMGB1 release remain poorly elucidated. Emerging evidence has suggested an essential role for the inflammasome in the regulation of LPS/ATP-induced HMGB1 release (7,12), because genetic disruption of key inflammasome components (for example, caspase 1 or Nalp3) impaired the LPS/ATP-induced HMGB1 release. Recently, we discovered that the double-stranded RNA-activated protein kinase R (PKR) functions as the key regulator of

Address correspondence to Haichao Wang or Wei Li, Department of Emergency Medicine, North Shore University Hospital, 350 Community Drive, Manhasset, NY 11030, USA; Phone: 516-562-2823; Fax: 516-562-1022; E-mail: hwang@nshs.edu, wli2@nshs.edu. Submitted June 19, 2013; Accepted for publication July 1, 2013; Epub (www.molmed.org) ahead of print July 1, 2013.




Figure 1. Chemical structures of a major ganciao component and derivatives. The major ganciao component GZA can be metabolized into glycyrrhithinic acid (GTA) via the glycanonidase-mediated hydrolysis *in vivo*. GTA (also called enoxolone) can be chemically derivatized by esterification into a succinate ester termed “carbenoxolone.”

inflammasome activation and HMGB1 release (7). It has been suggested that LPS activates the inflammasome signaling pathways partly through eliciting the passive ATP leakage (13). Indeed, ultra-pure LPS (free from contaminating bacterial proteins and nucleic acids) fails to trigger HMGB1 release unless the initial LPS (10 µg/mL) priming is accompanied by a second stimulus (for example, ATP) (7,12). Similarly, ATP itself is unable to induce HMGB1 release without prior LPS exposure (12), although it can induce PKR phosphorylation (7) and inflammasome activation (14–16).

It has been suggested that ATP activates the inflammasome through binding to the purinergic P2X₇ receptor (P2X₇R) (5), which triggers an immediate (within milliseconds) opening of the ATP-gated P2X₇R channel permeable for small cationic ions. Subsequently, the pannexin-1 (panx-1) hemichannels are recruited and activated, allowing passage of larger anionic molecules up to 900 Da (for example, ATP) (17–19). This feed-forwarding ATP-mediated ATP release contributes to the LPS-stimulated inflammasome activation (20) and subsequent inflammasome-dependent cytokine release (for example, IL-1β and IL-18) (14–16,21,22). It is not known whether agents capable of inhibiting the panx-1 hemichannel can inhibit LPS-induced PKR activation and HMGB1 release, thereby conferring protection against lethal sepsis.

Ganciao (*Radix Glycyrrhizae*; licorice) has been used traditionally in the clinical

management of various inflammatory ailments including peptic ulcer, hepatitis and pulmonary bronchitis for many centuries. Its antiinflammatory properties are attributable to a major component, glycyrrhizin (glycyrrhizic acid, GZA) (Figure 1), which has been proven beneficial in animal models of influenza (23), hepatitis (24), endotoxemia (25), lung inflammation (26) and colitis (27). The replacement of the glucuronic acid in GZA by succinic acid gives rise to a new compound, carbenoxolone (CBX), a licensed drug prescribed in the UK for esophageal ulceration and inflammation (28). Unlike GZA, CBX (10 µmol/L) can effectively inhibit the panx-1 hemichannel-mediated ATP release in response to hypoxia (29), shear stress (30) and low oxygen tension (31). Furthermore, CBX can inhibit LPS-induced dye uptake (17,32), and confer protection against LPS-induced acute lung injury (33) or cerebral ischemic injury (34). It was previously unknown whether CBX can inhibit endotoxin-induced HMGB1 release and protects animals against lethal sepsis. In this study, we demonstrated that CBX remarkably inhibited endotoxin-induced HMGB1 release possibly through blocking P2X₇R-gated panx-1 channels, and rescued mice from lethal sepsis. In addition, the blockade of panx-1 channels by CBX and P2X₇R antagonists correlated with an inhibition of LPS-induced PKR activation, suggesting a critical role of P2X₇R-gated panx-1 channels in the reg-

ulation of PKR-mediated inflammasome activation and inflammatory responses.

MATERIAL AND METHODS

Materials

Bacterial endotoxin (lipopolysaccharide, LPS, *E. coli* 0111:B4), CBX (C4790), KN-62 (I2142), adenosine 5'-triphosphate-2',3'-dialdehyde (oxidized ATP, oATP, A6779), brilliant blue G (BBG, B0770), Lucifer Yellow (L0144), paraformaldehyde (P6148) and mouse anti-β-actin antibodies (A1978) were obtained from Sigma-Aldrich (St. Louis, MO, USA). Calcein-AM (C3099), CM-DiI (C7001), Dulbecco's modified Eagle medium (DMEM, 11995-065), penicillin/streptomycin (cat. 15140-122), fetal bovine serum (FBS, 26140079) and trypan blue (15250-061) were from Invitrogen/Life Technologies (Carlsbad, CA, USA). Anti-LC3 antibody (sc-16755), anti-PKR antibody (sc-6282), and HRP conjugated goat anti-mouse IgG (sc-2060) were from Santa Cruz Biotechnology Inc., Dallas, TX, USA. Anti-phosphorylated PKR antibody (07-886) was from Millipore (Billerica, MA, USA). HRP conjugated donkey anti-rabbit IgG was from GE Healthcare (NA934; Port Washington, NY, USA).

Cell Culture

Murine macrophagelike RAW 264.7 cells were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). Primary peritoneal macrophages were isolated from BALB/c mice (Taconic, Germantown, NY, USA);

male, 7–8 wks, 20–25 g) at 2–3 d after intraperitoneal injection of 2 mL thioglycolate broth (4%) as described previously (35,36). Both RAW 264.7 cells and primary macrophages were cultured in DMEM supplemented with 1% penicillin/streptomycin and 10% FBS. Adherent macrophages were gently washed with, and cultured in, DMEM before stimulating with LPS (0.5 µg/mL) in the absence or presence of CBX or purinergic P2X₇R antagonists (oATP, 50 µmol/L; BBG, 0.5 µmol/L; KN62, 0.5 µmol/L) for 16 h. Subsequently, the cell-conditioned culture media were analyzed for levels of HMGB1, nitric oxide (NO) and other cytokines by Western blotting analysis, the Griess reaction, ELISA, and cytokine antibodies arrays as described previously (36–38).

Cell Viability Assay

Cell viability was assessed by the trypan blue exclusion assay as described previously (39,40). Briefly, trypan blue was added to cell cultures at a final concentration of 0.08%. After incubation for 5 min at room temperature, the cell viability was assessed by the percentage of dye-excluding cells in five 40× microscope fields.

Western Blotting

The levels of HMGB1 in the culture medium, serum or peritoneal lavage fluid were determined by Western blotting analysis as described previously (6,41,42). The levels of total or phosphorylated PKR in primary macrophage cell lysates were determined by Western blotting analysis with reference to β-actin. Briefly, equal amounts of cellular proteins were resolved on sodium dodecyl sulfate (SDS)-polyacrylamide gels, and transferred to polyvinylidene difluoride (PVDF) membranes. After blocking with 5% nonfat milk, the membrane was incubated with respective antibodies (anti-PKR, 1:2000; anti-phospho-PKR, 1:1000; anti-β-actin, 1:5000) overnight. Subsequently, the membrane was incubated with the appropriate secondary antibody, and the immunoreactive bands were visualized by chemiluminescence technique.

TNF ELISA

The levels of TNF in the culture medium or serum were determined using commercial enzyme linked immunosorbent assay (ELISA) kits (MTA00, R&D Systems, Minneapolis, MN, USA) with reference to standard curves of purified recombinant TNF at various dilutions as described previously (37,38,42–44).

Nitric Oxide Assay

The levels of nitric oxide in the culture medium were determined indirectly by measuring the NO²- production with a colorimetric assay based on the Griess reaction (35,40). NO²- concentrations were determined with reference to a standard curve generated with sodium nitrite at various dilutions.

Cytokine Antibody Array

Murine cytokine antibody arrays (M0308003, RayBiotech Inc., Norcross, GA, USA), which detect 62 cytokines on one membrane, were used to determine serum cytokine levels as described previously (35,40). Briefly, the membranes were sequentially incubated with equal volumes of murine serum (after 1:10 dilution), primary biotin-conjugated antibodies, and horseradish peroxidase-conjugated streptavidin. After exposing to X-ray film, the relative signal intensity was determined using the Scion Image software.

Lucifer Yellow Dye Uptake Assay

The Lucifer Yellow dye uptake was used to measure the P2X₇R-gated channel activities as described previously (17,45,46). Briefly, RAW 264.7 cells were stimulated with LPS in the absence or presence of CBX or other P2X₇R receptor antagonists (KN-62, BBG, or oATP) for 16 h. Subsequently, cell cultures were incubated with Lucifer Yellow (LY, 1 mg/mL) for 15 min, and fixed with 2% paraformaldehyde following three extensive washes with 1 × PBS. The number of cells with diffused fluorescent signals was counted under a fluorescence microscope. The cells containing punctuate fluorescent signals were excluded, as the punctuate signals likely resulted from phagocytosis

(rather than passive diffusion through panx-1 hemichannels) of the LY dye.

Animal Model of Polymicrobial Sepsis

This study was approved and performed in accordance with the guidelines of the Institutional Animal Care and Use Committee of the Feinstein Institute for Medical Research, Manhasset, New York, USA. To evaluate the therapeutic potential of CBX, a clinically relevant animal model of sepsis induced by cecal ligation and puncture (CLP) was employed (37,38,47). Briefly, the cecum of BALB/c mice was ligated at 5.0 mm from the cecal tip, and then punctured once with a 22-gauge needle. CBX was administered intraperitoneally into mice at indicated doses and time points, and animal survival rates were monitored for up to 2 wks. In parallel experiments, mice were euthanized to collect blood or peritoneal lavage fluid at 50 h (2 h after the second dose of CBX) after CLP, and assayed for serum levels of TNF, HMGB1 and other cytokines, as described previously (48).

Statistical Analysis

Data are expressed as mean (SEM) of two independent experiments in triplicates (n = 2). One-way analyses of variance (ANOVA) followed by the Tukey test for multiple comparisons were used to compare between different groups. The Kaplan-Meier method was used to compare the differences in mortality rates between groups. A *P* value <0.05 was considered statistically significant.

RESULTS

CBX Dose Dependently Attenuated Endotoxin-Induced HMGB1 Release

To elucidate the mechanisms underlying the endotoxin-mediated HMGB1 release, we evaluated the antiinflammatory properties of a major ganciao component (GZA) and its derivative (CBX) *in vitro*. Consistent with previous reports (25,49), GZA dose dependently inhibited endotoxin-induced release of nitric oxide and TNF in murine macrophagelike RAW




Figure 2. CBX effectively abrogated LPS-induced HMGB1 release in macrophage cultures. Murine macrophagelike RAW 264.7 cells (panel A) or primary peritoneal macrophages (panel B) were stimulated with LPS in the absence or presence of CBX at indicated concentrations. At 16 h after stimulation, the levels of HMGB1, TNF and nitric oxide in the culture medium were respectively determined by Western blotting, ELISA and Griess reactions, and expressed in arbitrary units (AU). * $P < 0.05$ versus negative control (– LPS); # $P < 0.05$ versus positive control (+ LPS alone).

264.7 cells (data not shown). Similarly, CBX dose dependently inhibited LPS-induced HMGB1 release in both RAW 264.7 cells (Figure 2A) and primary peritoneal macrophage cultures (Figure 2B), with an estimated IC_{50} and IC_{100} approximately 5 μ mol/L and 10 μ mol/L, respectively. At the concentrations effective for abrogating HMGB1 release, CBX only partly (by ~40%) attenuated LPS-induced nitric oxide production without significantly affecting TNF secretion in RAW 264.7 cells (see Figure 2A). Similarly, CBX only partially inhibited LPS-induced TNF secretion and nitric oxide production in primary peritoneal macrophage cultures (see Figure 2B), suggesting CBX as an effective HMGB1 inhibitor in macrophage cultures.

The CBX-mediated inhibition of HMGB1 release was not dependent on its cytotoxic activities, as CBX did not reduce cell viability at concentrations up to 20 μ mol/L (data not shown). At higher

concentrations (50 μ mol/L), however, CBX did exhibit noticeable cytotoxicity to RAW 264.7 cells, but not to primary peritoneal macrophages. These observations were consistent with previous findings that prolonged incubation with CBX resulted in cytotoxicity in other tumor cell lines (50). Accordingly, we chose to use nontoxic doses of CBX (10 μ mol/L) for most experiments in the present studies unless otherwise noted.

CBX Rescued Mice from Lethal Polymicrobial Sepsis

In light of the pathogenic role of HMGB1 in lethal sepsis (8), we explored the therapeutic potential of CBX using a clinically relevant animal model of polymicrobial sepsis induced by CLP. The first dose of CBX was given 24 h after CLP, a time point at which mice developed clear signs of sepsis including lethargy, diarrhea and piloerection. Repeated administration of CBX beginning





Figure 3. Delayed administration of CBX rescued mice from lethal sepsis. BALB/c mice were subjected to lethal sepsis (induced by CLP), and intraperitoneally administered with saline (0.2 mL/mouse) or CBX at indicated doses at +24, +48 and +72 h after CLP. Animal survival rates were monitored for 2 wks, and the Kaplan-Meier method was used to compare the differences between groups. * $P < 0.05$ versus saline control group.

24 h after the onset of sepsis (followed by additional doses at 48 and 72 h after CLP) conferred a dose-dependent and significant protection against lethal sepsis (Figures 3A, B), supporting a therapeutic potential for CBX in the treatment of sepsis.



CBX Selectively Attenuated Sepsis-Induced Local and Systemic HMGB1 Accumulation

To gain insight into its protective mechanism, we evaluated the effects of CBX on the systemic accumulation of various cytokines by cytokine antibody arrays. At late stages of experimental sepsis (for example, 50 h after CLP), most early cytokines (including IL-1 β and TNF) were no longer detectable in the circulation of septic mice (Figure 4A). A few other cytokines (for example, BLC,

A Serum Cytokine Antibody Arrays



B Serum WB



C Peritoneal lavage fluid WB





Figure 4. CBX attenuated sepsis-induced HMGB1 accumulation. BALB/c mice were subjected to sepsis by CLP, and administered with control saline (0.2 mL/mouse) or CBX (6.0 mg/kg) at 24 and 48 h CLP. At 50 h after CLP, the levels of HMGB1 and various cytokines in the serum (Panel A,B) and peritoneal lavage fluid (Panel C) were determined by cytokine antibody arrays (Panel A) and Western blotting analysis (Panel B, C), respectively. The relative HMGB1 levels were expressed as mean \pm SD of two independent experiments ($n = 2$) in arbitrary units. * $P < 0.05$ versus saline group (+ CLP).

G-CSF and P-selectin) were still elevated at a late stage of sepsis, but their levels were not affected by CBX administration (see Figure 4A). In a sharp contrast, CBX significantly reduced HMGB1 levels not only systemically in the circulation (Figure 4B), but also locally in the peritoneal lavage fluid (Figure 4C), suggesting that

CBX confers protection against lethal sepsis possibly by attenuating local and systemic HMGB1 accumulation.

CBX Effectively Inhibited P2X₇R-Gated Channel Activities

To elucidate the mechanisms underlying the CBX-mediated HMGB1 inhibition,

we determined whether CBX affects ATP-gated channel activities in macrophage cultures. The ATP-gated channel activities were judged by the cellular uptake of an anionic dye, Lucifer Yellow (LY, MW = 444 Da), which spontaneously fluoresces even after being covalently linked to surrounding biomolecules by formaldehyde

fixation. In quiescent macrophages, approximately 2% cells displayed diffuse fluorescent signal after LY incubation (Figure 5A, left panels). Consistent with a previous report that LPS upregulated P2X₇R expression (21), we found that prolonged LPS stimulation resulted in an elevation in the number of LY-positive cells (Figure 5A, middle panels), suggesting that LPS elevated P2X₇R-gated channel activities. However, CBX significantly impaired the LPS-induced elevation of LY uptake (Figure 5A, right panels), suggesting that CBX effectively inhibits LPS-induced HMGB1 release, possibly by blocking P2X₇R-gated channel activities.

To test this possibility, we determined whether specific P2X₇R antagonists similarly inhibit LPS-induced HMGB1 release. As predicted, two selective P2X₇R antagonists, oATP and BBG, significantly inhibited LPS-induced LY-uptake in macrophage cultures (Figure 5B). Consistently, both P2X₇R antagonists effectively inhibited LPS-induced HMGB1 release (Figure 5C). Surprisingly, another selective P2X₇R antagonist, KN62, was ineffective in suppressing LPS-induced LY uptake (see Figure 5B), and similarly failed to inhibit LPS-induced HMGB1 release (see Figure 5C). Taken together, these observations demonstrate a strong correlation between P2X₇R-gated channel activity and HMGB1 release in macrophages.

CBX Prevented LPS-Induced PKR Upregulation and Phosphorylation

In light of the roles of P2X₇R and PKR in LPS/ATP-induced inflammasome activation (7,20), we tested the effects of CBX and P2X₇R antagonists (for example, oATP) on LPS-induced PKR activation in primary macrophage cultures. Interestingly, prolonged stimulation with crude LPS (containing trace amounts of bacterial proteins and nucleic acids) resulted in a > two-fold increase in total cellular PKR protein levels (Figure 6A), but a more robust (> eight-fold) elevation in phospho-PKR levels (see Figure 6A). Furthermore, this LPS-induced elevation of PKR expression and phosphorylation was both significantly attenuated by CBX (see




Figure 5. CBX and P2X₇R antagonists inhibited LPS-induced dye uptake and HMGB1 release. A), CBX attenuated LPS-induced elevation of dye uptake. Murine macrophage cultures were stimulated with LPS for 16 h, and subsequently incubated with the LY dye for 15 min. The number of LY dye-positive cells were counted and expressed as a percentage of total number of cells in multiple fields. **P* < 0.05 versus negative control; #*P* < 0.05 versus positive control (+ LPS alone). B, C), P2X₇R antagonists attenuated LPS-induced elevation of dye uptake and HMGB1 release. Macrophage cultures were stimulated with LPS (0.5 μg/mL) in the absence or presence of several P2X₇R antagonists, KN62 (0.5 μmol/L), BBG (0.5 μmol/L), and oATP (50.0 μmol/L). At 16 h after LPS stimulation, the P2X₇R activities were determined by the LY dye uptake assays, and the levels of HMGB1 in the culture medium were determined by Western blotting analysis. **P* < 0.05 versus negative control (– LPS); #*P* < 0.05 versus positive control (+ LPS alone).




Figure 6. CBX attenuated LPS-induced PKR upregulation and phosphorylation in macrophage cultures. Primary peritoneal macrophages were stimulated with crude LPS in the absence or presence of CBX (panel A) or P2X₇R antagonists (oATP; panel B) for 16 h, and cellular levels of total or phosphorylated PKR were determined by Western blotting analysis with reference to a housekeeping protein, β-actin. **P* < 0.05 versus negative control (– LPS and – CBX). #*P* < 0.05 versus positive controls (+ LPS alone).

Figure 6A) and oATP (Figure 6B), suggesting important roles for P2X₇-gated channels in the regulation of PKR-mediated inflammatory responses.

DISCUSSION

Many medicinal herbs have been developed into effective therapies for various inflammatory ailments. In this study, we demonstrated that CBX, a derivative of ganciclovir component GZA, effectively inhibited endotoxin-induced HMGB1 release, likely through blocking P2X₇-gated panx-1 channels, and rescued mice from lethal sepsis even when given at relative lower doses (1.2–6 mg/kg) in a delayed regimen (24 h after CLP), possibly through reducing both local and systemic HMGB1 levels.

Since its inception, CBX has been shown to dose dependently inhibit a variety of biological activities including the gap junctions (50–100 $\mu\text{mol/L}$), panx-1 channels ($\text{EC}_{50} = 1\text{--}4\text{ }\mu\text{mol/L}$) (51,52), and 11 β -hydroxysteroid dehydrogenase (1–10 $\mu\text{mol/L}$, 11 β -HSD) (53). However, it is unlikely that CBX inhibits LPS-induced HMGB1 release through impairing the gap junctions. First, macrophages did not form gap junctions even after prolonged LPS stimulation, although the cellular panx-1 levels might be elevated (data not shown). Second, the concentrations of CBX used to block gap junctions (for example, 50–100 $\mu\text{mol/L}$) are much higher than those (for example, 5–10 $\mu\text{mol/L}$) used to abrogate LPS-induced HMGB1 release. In fact, at relative high concentrations (50–100 $\mu\text{mol/L}$), CBX exhibited cytotoxicity to RAW 264.7 cells, thereby enhancing (rather than reducing) passive HMGB1 leakage. Thus, it appears that CBX inhibits HMGB1 release through gap junction-independent mechanisms. Similarly, it is unlikely that CBX exerts its inhibition on LPS-induced HMGB1 release through inhibiting 11 β -HSD, an enzyme involved in the production of antiinflammatory glucocorticoids. Our previous study indicated that glucocorticoids such as cortisone and dexamethasone were ineffective in inhibiting LPS-induced HMGB1 release in macrophage cultures

(40), arguing against the possibility that CBX abrogated HMGB1 release by inhibiting 11 β -HSD1.

The possibility for the involvement of panx-1 in CBX-mediated inhibition of HMGB1 release is supported by several lines of evidence. First, unlike other pannexin family members, panx-1 is expressed abundantly on macrophage cytoplasmic membranes. Even though panx-1 may not form gap junctions, it can integrate into hemichannels in macrophages or astrocytes. These panx-1 hemichannels are gated by ATP receptors (for example, P2X₇R) and responsible for the increased dye-uptake upon ATP stimulation. Second, as an effective panx-1 channel inhibitor ($\text{IC}_{50} < 5\text{ }\mu\text{mol/L}$), CBX simultaneously inhibited LPS-induced P2X₇R/panx-1 channel activation and HMGB1 release, suggesting that the CBX-mediated inhibition of HMGB1 release is likely associated with the blockade of P2X₇-gated




Figure 7. Proposed model for CBX-mediated inhibition of HMGB1 release. Prolonged stimulation with crude LPS may lead to panx-1 hemichannel-mediated ATP efflux, and upregulation of PKR expression. Extracellular ATP then binds to P2X₇R and activates the ATP-gated P2X₇R and panx-1 channels, leading to PKR phosphorylation and subsequent inflammasome-dependent HMGB1 release. As a panx-1 inhibitor, CBX may block LPS-induced ATP efflux, thereby impairing ATP/P2X₇R-mediated PKR activation, and subsequent inflammasome-dependent HMGB1 release.

panx-1 channel activities. Consistent with this notion, CBX and other panx-1 channel blockers have recently been shown to block HMGB1 release by neurons during cortical spreading depression (54).

Additionally, we discovered that CBX and P2X₇R antagonists similarly inhibit LPS-induced phosphorylation of PKR, a newly identified regulator of inflammasome activation and HMGB1 release (7). Therefore, we propose that LPS may prime macrophages by upregulating PKR expression and possibly eliciting panx-1-mediated ATP release. Extracellular ATP activates the P2X₇R and causes further elevation of panx-1 channel activity, leading to massive PKR activation and subsequent HMGB1 release (Figure 7). This possibility is consistent with previous findings that panx-1 physically interacts with both P2X₇R and components of the NLRP3 inflammasome (17,55). It also is supported by our observations that both

P2X₇R antagonists (for example, oATP) and panx-1 inhibitors (for example, CBX) effectively inhibited LPS-induced dye uptake, PKR activation, and HMGB1 release. In light of previous reports that CBX inhibited panx-1 hemichannel-mediated ATP release (19,29–31) and passage of anionic dyes (17,51,52), it is tempting to propose that CBX attenuates LPS-induced HMGB1 release by limiting the availability of extracellular ATP to the P2X₇R, thereby impairing activation of ATP-gated channels and PKR. This possibility is in agreement with the findings that ATP serves as the second stimuli for the release of other inflammasome-dependent cytokines (for example, IL-1 β or IL-18) in LPS-primed macrophages (14–16).

Previously, we, and others, have demonstrated that extracellular accumulation of HMGB1 can be attenuated by HMGB1 inhibitors through distinct mechanisms. For instance, mung bean extracts and green tea components (for example, EGCG) prevent extracellular HMGB1 release through stimulating HMGB1 aggregation and autophagic degradation (38,43). Danshen components (for example, tanshinone IIA sodium sulphonate) effectively stimulate endocytic HMGB1 uptake, thereby recycling extracellular HMGB1 back to cytoplasmic vesicles for eventual degradation (36). In a sharp contrast, CBX could neither induce autophagic HMGB1 degradation, nor stimulate endocytic HMGB1 uptake in macrophage cultures (data not shown). Instead, it blocks the LPS-induced activation of P2X₇R/panx-1 channels, indicating the selective targeting of LPS-triggered inflammatory signaling cascade in macrophages (see Figure 7). This is noteworthy especially in light of observations that CBX appears to be more effective in blocking the release of HMGB1 than NO and TNF *in vitro* and in selectively attenuating circulating HMGB1 in septic mice. It is plausible that, as a molecular target of CBX, the P2X₇R-gated channels occupy a more important role in the regulation of late (rather than early) mediator of lethal sepsis.

CONCLUSION

In summary, we have validated the therapeutic potential of CBX in an animal model of polymicrobial sepsis by administering it in a delayed regimen. Furthermore, we have uncovered a novel mechanism by which CBX effectively inhibits HMGB1 release possibly by blocking P2X₇R-gated channels and preventing endotoxin-induced PKR activation. Given the central role of PKR in the regulation of inflammasome activation and HMGB1 release, it is important to further delineate the role of P2X₇R-gated channels in inflammatory diseases and explore novel PKR-targeting therapeutic strategies.

ACKNOWLEDGMENTS

We thank Mala Ashok for assistance with animal experiments, Arvin Jundoria for critical reading of the manuscript, and Kevin J Tracey and Ben Lu for helpful discussions. This work was supported by the National Center of Complementary and Alternative Medicine (NCCAM, R01AT05076) and the National Institute of General Medical Sciences (NIGMS, R01GM063075).

DISCLOSURES

The authors declare that they have no competing interests as defined by *Molecular Medicine*, or other interests that might be perceived to influence the results and discussion reported in this paper.

REFERENCES

- Angus DC, *et al.* (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. *Crit. Care Med.* 29:1303–10.
- Ayala A, Song GY, Chung CS, Redmond KM, Chaudry IH. (2000) Immune depression in polymicrobial sepsis: the role of necrotic (injured) tissue and endotoxin. *Crit. Care Med.* 28:2949–55.
- Xiang M, Fan J. (2010) Pattern recognition receptor-dependent mechanisms of acute lung injury. *Mol. Med.* 16:69–82.
- Chen GY, Tang J, Zheng P, Liu Y. (2009) CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. *Science.* 323:1722–5.
- Surprenant A, Rassendren F, Kawashima E, North RA, Buell G. (1996) The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X₇). *Science.* 272:735–8.
- Wang H, *et al.* (1999) HMG-1 as a late mediator of endotoxin lethality in mice. *Science.* 285:248–51.
- Lu B, *et al.* (2012) Novel role of PKR in inflammasome activation and HMGB1 release. *Nature.* 488:670–4.
- Yang H, *et al.* (2004) Reversing established sepsis with antagonists of endogenous high-mobility group box 1. *Proc. Natl. Acad. Sci. U. S. A.* 101:296–301.
- Wang H, Yang H, Czura CJ, Sama AE, Tracey KJ. (2001) HMGB1 as a late mediator of lethal systemic inflammation. *Am. J. Respir. Crit. Care Med.* 164:1768–73.
- Qin S, *et al.* (2006) Role of HMGB1 in apoptosis-mediated sepsis lethality. *J. Exp. Med.* 203:1637–42.
- Wang H, Zhu S, Zhou R, Li W, Sama AE. (2008) Therapeutic potential of HMGB1-targeting agents in sepsis. *Expert. Rev. Mol. Med.* 10:e32.
- Lamkanfi M, *et al.* (2010) Inflammasome-dependent release of the alarmin HMGB1 in endotoxemia. *J. Immunol.* 185:4385–92.
- Ali SR, *et al.* (2011) Anthrax toxin induces macrophage death by p38 MAPK inhibition but leads to inflammasome activation via ATP leakage. *Immunity.* 35:34–44.
- Mehta VB, Hart J, Wewers MD. (2001) ATP-stimulated release of interleukin (IL)-1 β and IL-18 requires priming by lipopolysaccharide and is independent of caspase-1 cleavage. *J. Biol. Chem.* 276:3820–6.
- Griffiths RJ, Stam EJ, Downs JT, Otterness IG. (1995) ATP induces the release of IL-1 from LPS-primed cells in vivo. *J. Immunol.* 154:2821–8.
- Perregaux DG, McNiff P, Laliberte R, Conklyn M, Gabel CA. (2000) ATP acts as an agonist to promote stimulus-induced secretion of IL-1 β and IL-18 in human blood. *J. Immunol.* 165:4615–23.
- Pelegrin P, Surprenant A. (2006) Pannexin-1 mediates large pore formation and interleukin-1 β release by the ATP-gated P2X₇ receptor. *EMBO J.* 25:5071–82.
- Locovei S, Scemes E, Qiu F, Spray DC, Dahl G. (2007) Pannexin1 is part of the pore forming unit of the P2X₇ receptor death complex. *FEBS Lett.* 581:483–8.
- Baroja-Mazo A, Barbera-Cremades M, Pelegrin P. (2013) The participation of plasma membrane hemichannels to purinergic signaling. *Biochim. Biophys. Acta.* 1828:79–93.
- Di Virgilio F. (2007) Liaisons dangereuses: P2X₇ and the inflammasome. *Trends Pharmacol. Sci.* 28:465–72.
- Humphreys BD, Dubyak GR. (1996) Induction of the P2Z/P2X₇ nucleotide receptor and associated phospholipase D activity by lipopolysaccharide and IFN- γ in the human THP-1 monocytic cell line. *J. Immunol.* 157:5627–37.
- Ferrari D, Chiozzi P, Falzoni S, Hanau S, Di Virgilio F. (1997) Purinergic modulation of interleukin-1 β release from microglial cells stimulated with bacterial endotoxin. *J. Exp. Med.* 185:579–82.
- Utsunomiya T, Kobayashi M, Pollard RB, Suzuki F.

- (1997) Glycyrrhizin, an active component of licorice roots, reduces morbidity and mortality of mice infected with lethal doses of influenza virus. *Antimicrob. Agents Chemother.* 41:551–6.
24. Okamoto T, Kanda T. (1999) Glycyrrhizin protects mice from concanavalin A-induced hepatitis without affecting cytokine expression. *Int. J. Mol. Med.* 4:149–52.
 25. Yoshida T, *et al.* (2007) Inhibitory effect of glycyrrhizin on lipopolysaccharide and d-galactosamine-induced mouse liver injury. *Eur. J. Pharmacol.* 576:136–42.
 26. Menegazzi M, *et al.* (2008) Glycyrrhizin attenuates the development of carrageenan-induced lung injury in mice. *Pharmacol. Res.* 58:22–31.
 27. Liu Y, *et al.* (2011) Protective effects of glycyrrhizinic acid by rectal treatment on a TNBS-induced rat colitis model. *J. Pharm. Pharmacol.* 63:439–46.
 28. Shearman DJ, Hetzel D. (1979) The medical management of peptic ulcer. *Annu. Rev. Med.* 30:61–79.
 29. Thompson RJ, Zhou N, MacVicar BA. (2006) Ischemia opens neuronal gap junction hemichannels. *Science.* 312:924–7.
 30. Reigada D, Lu W, Zhang M, Mitchell CH. (2008) Elevated pressure triggers a physiological release of ATP from the retina: Possible role for pannexin hemichannels. *Neuroscience.* 157:396–404.
 31. Sridharan M, *et al.* (2010) Pannexin 1 is the conduit for low oxygen tension-induced ATP release from human erythrocytes. *Am. J. Physiol. Heart Circ. Physiol.* 299: H1146–52.
 32. Pelegrin P, Surprenant A. (2009) Dynamics of macrophage polarization reveal new mechanism to inhibit IL-1 β release through pyrophosphates. *EMBO J.* 28:2114–27.
 33. Suzuki S, *et al.* (2004) Effects of carbenoxolone on alveolar fluid clearance and lung inflammation in the rat. *Crit. Care Med.* 32:1910–5.
 34. Tamura K, Alessandri B, Heimann A, Kempinski O. (2011) The effect of a gap-junction blocker, carbenoxolone, on ischemic brain injury and cortical spreading depression. *Neuroscience.* 194:262–71.
 35. Li W, *et al.* (2007) A major ingredient of green tea rescues mice from lethal sepsis partly by inhibiting HMGB1. *PLoS ONE* 2:e1153.
 36. Zhang Y, *et al.* (2012) Tanshinone IIA sodium sulfonate facilitates endocytic HMGB1 uptake. *Biochem. Pharmacol.* 84:1492–500.
 37. Li W, *et al.* (2011) A hepatic protein, fetuin-A, occupies a protective role in lethal systemic inflammation. *PLoS ONE* 6:e16945.
 38. Li W, *et al.* (2011) EGCG stimulates autophagy and reduces cytoplasmic HMGB1 levels in endotoxin-stimulated macrophages. *Biochem. Pharmacol.* 81:1152–63.
 39. Chen G, *et al.* (2004) Bacterial endotoxin stimulates macrophages to release HMGB1 partly through CD14- and TNF-dependent mechanisms. *J. Leukoc. Biol.* 76:994–1001.
 40. Li W, *et al.* (2007) A cardiovascular drug rescues mice from lethal sepsis by selectively attenuating a late-acting proinflammatory mediator, high mobility group box 1. *J. Immunol.* 178:3856–64.
 41. Rendon-Mitchell B, *et al.* (2003) IFN- γ induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. *J. Immunol.* 170:3890–7.
 42. Wang H, *et al.* (2006) The aqueous extract of a popular herbal nutrient supplement, *Angelica sinensis*, protects mice against lethal endotoxemia and sepsis. *J. Nutr.* 136:360–5.
 43. Zhu S, *et al.* (2012) It is not just folklore: the aqueous extract of mung bean coat is protective against sepsis. *Evid. Based. Complement Alternat. Med.* 2012:498467.
 44. Chen G, *et al.* (2004) Bacterial endotoxin stimulates macrophages to release HMGB1 partly through CD14- and TNF-dependent mechanisms. *J. Leukoc. Biol.* 76:994–1001.
 45. Schachter J, *et al.* (2008) ATP-induced P2X7-associated uptake of large molecules involves distinct mechanisms for cations and anions in macrophages. *J. Cell Sci.* 121:3261–70.
 46. Cankurtaran-Sayar S, Sayar K, Ugur M. (2009) P2X7 receptor activates multiple selective dye-permeation pathways in RAW 264.7 and human embryonic kidney 293 cells. *Mol. Pharmacol.* 76:1323–32.
 47. Li W, *et al.* (2012) Use of animal model of sepsis to evaluate novel herbal therapies. *J. Vis. Exp.* (62):3926.
 48. Zhu S, *et al.* (2009) Spermine protects mice against lethal sepsis partly by attenuating surrogate inflammatory markers. *Mol. Med* 15:275–82.
 49. Tang B, Qiao H, Meng F, Sun X. (2007) Glycyrrhizin attenuates endotoxin-induced acute liver injury after partial hepatectomy in rats. *Braz. J. Med. Biol. Res.* 40:1637–46.
 50. Davidson JS, Baumgarten IM, Harley EH. (1986) Reversible inhibition of intercellular junctional communication by glycyrrhetic acid. *Biochem. Biophys. Res. Commun.* 134:29–36.
 51. Ma W, Hui H, Pelegrin P, Surprenant A. (2009) Pharmacological characterization of pannexin-1 currents expressed in mammalian cells. *J. Pharmacol. Exp. Ther.* 328:409–18.
 52. Poornima V, *et al.* (2012) P2X7 receptor-pannexin 1 hemichannel association: effect of extracellular calcium on membrane permeabilization. *J. Mol. Neurosci.* 46:585–94.
 53. Bujalska I, Shimojo M, Howie A, Stewart PM. (1997) Human 11 β -hydroxysteroid dehydrogenase: studies on the stably transfected isoforms and localization of the type 2 isozyme within renal tissue. *Steroids.* 62:77–82.
 54. Karatas H, *et al.* (2013) Spreading depression triggers headache by activating neuronal Panx1 channels. *Science.* 339:1092–5.
 55. Dahl G, Keane RW. (2012) Pannexin: from discovery to bedside in 11 \pm 4 years? *Brain Res.* 1487:150–9.